Daclatasvir plus asunaprevir dual therapy for chronic HCV genotype 1b infection: results of Turkish early access program.
Köklü, Seyfettin
Daclatasvir plus asunaprevir dual therapy for chronic HCV genotype 1b infection: results of Turkish early access program. [electronic resource] - Annals of hepatology - 71-76 p. digital
Publication Type: Journal Article
1665-2681
10.5604/16652681.1226817 doi
Aged
Antiviral Agents--adverse effects
Carbamates
Cost-Benefit Analysis
Drug Costs
Drug Therapy, Combination
Female
Genotype
Health Services Accessibility--economics
Hepacivirus--drug effects
Hepatitis C, Chronic--diagnosis
Humans
Imidazoles--adverse effects
Isoquinolines--adverse effects
Male
Middle Aged
Program Evaluation
Pyrrolidines
RNA, Viral--genetics
Sulfonamides--adverse effects
Time Factors
Treatment Outcome
Turkey
Valine--analogs & derivatives
Viral Load
Daclatasvir plus asunaprevir dual therapy for chronic HCV genotype 1b infection: results of Turkish early access program. [electronic resource] - Annals of hepatology - 71-76 p. digital
Publication Type: Journal Article
1665-2681
10.5604/16652681.1226817 doi
Aged
Antiviral Agents--adverse effects
Carbamates
Cost-Benefit Analysis
Drug Costs
Drug Therapy, Combination
Female
Genotype
Health Services Accessibility--economics
Hepacivirus--drug effects
Hepatitis C, Chronic--diagnosis
Humans
Imidazoles--adverse effects
Isoquinolines--adverse effects
Male
Middle Aged
Program Evaluation
Pyrrolidines
RNA, Viral--genetics
Sulfonamides--adverse effects
Time Factors
Treatment Outcome
Turkey
Valine--analogs & derivatives
Viral Load